Clinical Trial: Blepharospasm Patient Survey for Patients With Blepharospasm

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients

Brief Summary: The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Detailed Summary: This study is open to males and females > 18 years and < 81 years with a clinical diagnosis of blepharospasm.
Sponsor: Merz Pharmaceuticals, LLC

Current Primary Outcome: Botulinum Toxin Treatment Information [ Time Frame: This is a single, structured interview about experiences with Botulinum Toxins ]

The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)


Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Merz Pharmaceuticals, LLC

Dates:
Date Received: September 12, 2012
Date Started: September 2012
Date Completion:
Last Updated: April 7, 2014
Last Verified: April 2014